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ABSTRACT
Objectives: This study aims to determine the amount of excipient that is degraded by alpha-amylase and the influence of alpha-amylase to the 
dissolution profile of sustained-release tablets that use matrix CL-Co-A-XG.
Methods: Excipient is cross-linked with two concentrations of sodium trimetaphospate, which are 6% (CL6-Co-A-XG) and 12% (CL12-Co-A-XG). 
Each excipient is made with the ratios 1:1, 1:2, and 2:1 amylose-xanthan gum. Enzymatic degradation tests are performed on excipient powders for 
60 minutes. Sustained-release tablet with CL-Co-A-XG excipient as a matrix is formulated through direct compression method. Then, drug dissolution 
tests are performed in a phosphate buffer with a pH of 7.4 both using and without using alpha-amylase as a medium for 8 hrs.
Results: The results of this study show that CL6-Co-A-XG and CL12-Co-A-XG degraded 20% at 10 and 30 minutes, respectively. In addition, the release 
profile of F1-F6 tablets show the sustained-release profile that follows zero-order and Korsmeyer–Peppas kinetics and is unaffected by the presence 
of alpha-amylase.
Conclusions: From this study, it can be concluded that the CL-Ko-A-XG excipients are more resistant to enzymatic degradation than amylose. Therefore, 
this excipient shows potential as a single matrix sustained-release tablet.
Keywords: Cross-linked of excipient co-processed xanthan gum-amylose, Alpha-amylase, Dissolution profile, Enzymatic degradation, 
Sustained-release tablet.
INTRODUCTION
Oral administration of drugs is a frequently used route of administration. 
Various forms of pharmaceutical preparations are developed around 
it. One of the fastest growing oral preparations today is the sustained-
release tablet. Sustained-release tablet preparations contain two 
or more doses of a drug, which are then released over time. The 
sustained-release preparation aims to decrease the frequency of drug 
administration for drugs with short half-lives. Reduced frequency of 
drug delivery will improve patient compliance and reduce the risk of 
fluctuations in blood levels when using the drug. The popular system 
used in sustained -release drugs is the matrix system. The polymers 
used in the preparation of the sustained-release preparation matrix 
should have characteristics that allow it to regulate its release of the 
drug and keep the form of the matrix during the drug’s release [1].
Polysaccharides have many hydroxyl groups, which cause the 
polysaccharides to have a high affinity for water. The hydroxyl groups 
in the polysaccharides make it possible to be modified both physically 
and chemically. Various polysaccharides have been modified and 
can be used as sustained-release tablet excipients; one of which is 
amylose. In his research, Ariani and Surini made such a modification 
by performing an amylose coupling cross-linked with xanthan gum to 
improve the ability of excipients in maintaining their shape [2]. Co-
processes are physical modifications of the excipient by combining 
two or more excipients, thereby producing excipients having better 
physical properties. Xanthan gum is a polysaccharide that is resistant to 
enzymatic degradation and has a good expanding index. Based on these 
studies, drug release tests from tablets with a xanthan gum-amylose 
cross-linked formula showed a slowdown in drug release [2].
Xanthan gum-amylose crosscut exchanger excipients have many 
functional advantages, but the amylose contained in cross-linked 
xanthan gum-amylose cross-linking excipients is a substrate of alpha-
amylase. Alpha-amylase is an enzyme produced by the pancreas and 
is present in the human digestive tract, especially the small intestine. 
Alpha-amylase will hydrolyze the α-D-bond (1→4) straight chain 
amylose glycosidic. Amylose degradation occurring in the presence 
of alpha-amylase within the human body may affect the dissolution 
of sustained-release tablets by accelerating drug release from the 
preparation. In this research, dissolution of sustained-release tablets 
in a medium containing alpha-amylase, with diclofenac sodium as 
the drug model, will be tested. The dissolution test was carried out in 
accordance with those listed in the USP 32 monographs of diclofenac 
sodium sustained release tablets, which was added α-amylase. In 
addition, an enzymatic degradation test of cross-linked xanthan gum-
amylose crosscurrent excipients is performed at pH and at similar 
conditions with the dissolution medium. By doing this research, we 
hope to know the amount of enzyme-degradable excipients as well as 
the effect of alpha-amylase on the tablet dissolution profile.
METHODS
Tools
Following tools that were used for this study: Drum dryer (R. 
Simon Dryers, Nottingham, England); vibrator mill (Retsch, Haan, 
Germany); a sifter set (Retsch, Haan, Germany); ultraviolet (UV)-
1800 spectrophotometer (Shimadzu, Kyoto, Japan); pH meters Eutech 
pH 510 (Eutech Instruments, Singapore, Singapore); analytical balance 
of Adam AFA - 210 LC (Adam Equipment, Connecticut, United States); 
thermal analyzer DSC 6 (Perkin Elmer, Ohio, United States); oven 
(Memmert, Schwabach, Germany); tablets (Korsch, Berlin, Germany); 
TAR-type friability tester (Erweka, Heusenstamm, Germany); TDT-08L 
type dissolution equipment (Electrolab, Mumbai, India); TBH 28 type 
hardness tester (Erweka, Heusenstamm, Germany); slurry term (Venier 
Caliper, Shandong, China); homogenizer EH 20112 (CKL Machinery, 
Research Article
PTMDS 2017 | The 1st Physics and Technologies in Medicine and Dentistry Symposium
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ijap.2017.v9s1.42_48
78
Puchong, Malaysia); and moisture balance analyzer (Mettler Toledo, 
Giesen, Germany).
Materials
The materials used for this study were: Diclofenac sodium (Yung 
Zip Chemical, Taiwan); Amylose (Shangqiu Kangmedia Bio Tech, 
China); Xanthan gum (CV, Tristars Chemicals, Indonesia); sodium 
trimetaphosphate (STMP) (Shangqiu Kangmedia Bio-Tech, China); 
Alpha-amylase porcine (Sigma, Missouri, United States); Avicel PH 
102, sodium hydroxide, hydrochloric acid, sulfuric acid, nitric acid, 
ammonium molybdate tetrahydrate, sodium hydroxide, sodium 
chloride, sodium bicarbonate, aqua destillata (Merck, Darmstadt, 
Germany); potassium dihydrogen phosphate, 96% ethanol (Brataco, 
Jakarta, Indonesia); ascorbic acid (Takeda, Tokyo, Japan); and iodine 
and potassium iodide (Mallinckrodt, Surrey, London).
Making excipients cross-linked co-process amylose-xanthan gum
Amylose and xanthan gum, each with a concentration of 3%, are 
dissolved in distilled water. Amylose and xanthan gum are mixed at 
predetermined ratios (1:1, 1:2, and 2:1) and homogenized at 3000 rpm 
for 30 minutes. The homogeneous mass is then dried with a drum drier 
at a temperature of 80±5°C. The obtained layer or flakes are mashed 
and sieved with 35 mesh sieves.
A total of 1800 mL of aquadest is heated to a temperature of 30°C, 
and then amylose-xanthan gum processed excipients, as much as 
140 g, is added in by stirring with a stirring magnetic until completely 
dispersed. A 10 N sodium hydroxide solution is used to maintain 
the pH during the reaction; pH 11-12. To each batch added 8.4 g 
of STMP dissolved in 132 mL (6.6% of total aquadest) as a cross-
linking agent, with continuous stirring using a homogenizer at a rate 
of 3000 rpm. The reaction continues for 1-4 hrs, and then stands for 
12 hrs until the pH levels out. Then, the suspension is neutralized 
by adding a solution of 7 N hydrochloric acid to pH 6. The solid is 
decanted and washed with ethanol; the washing continues until 
the filtrate gives negative results with the ammonium molybdate 
reagent (non-intensive yellow). The resulting powder is dried at 
room temperature for 48 hrs. The result produces granules and is 
sieved with 35 mesh sieves. The experiment is repeated, but with 
using 16.8 g of STMP.
Degree of substitution
The determination of degrees of substitution is carried out chemically 
at CL-Ko-A-XG excipients with concentrations of STMP 6% and 12% 
dysfunction agents. The amount of phosphate substitution in STMP 
as a cross-linking agent is determined through colorimetric method. 
The reagents used are reagent A (10% ascorbic acid solution), 
reagent B (0.42% ammonium molybdate tetrahydrate solution in 1 N 
sulfuric acid), and mixed reactants (mixture of 1.0 mL of reactant A and 
6.0 mL of reactant B).
A total of 100 mg of the sample is dried in a furnace at 600°C to ash. The 
ash is cooled and added into 8.0 mL of 1N sulfuric acid. Then, the sample 
ash is heated to a boiling water bath for 10 minutes to ensure solubility 
and also to ensure the phosphate conversion formed during the 
inbreeding into inorganic phosphate. Filtrate is filtered using Whatman 
40 and transferred to a 10.0 mL measuring flask, to which aquadest and 
0.1N sulfuric acid (1: 1) are then added. The 1.0 mL filtrate was pipetted 
and combined with aquadest and 0.1 N sulfuric acid (1: 1) to 10.0 mL. 
The sample is piped in at 3.0 mL and added 7.0 mL of the mixed reagent. 
The sample in the test tube is then shaken and incubated in a water bath 
at 45°C for 20 minutes and then cooled.
The blank is prepared by taking as much as 3.0 mL of aquadest 
mixture and 0.1N sulfuric acid (1:1) and combining 7.0 mL of the 
mixed reagent, and is then treated equally from the shaking stage. The 
absorption of the sample, blank, or standard, is measured by a viscous 
spectrophotometer at a wavelength of 820 nm because the sample 
has a blue color. Interpretation of phosphate concentration is done by 
extrapolating the uptake on a standard calibration curve made from 
the standard solution of potassium dihydrogen phosphate (100 μg P 
in 1 mL). Calibration curves are made at concentrations of 2.0 ppm, 
5.0 ppm, 10.0 ppm, 15.0 ppm, 20.0 ppm, and 25.0 ppm. The standard 
solution is piped at 3.0 mL and combined with 7.0 mL of the mixed 
reagent. The solution is shaken and incubated in a water bath at 45°C 
for 20 minutes, and then cooled.
The amount of substitution is determined using the following formula, 
where P represents% phosphorus (% P) of phosphorylated amylose [3]. 
The number 162 is the molecular weight of one glucose unit, the 
number 3100 is the molecular weight of phosphor (P) multiplied by 
100, and 102 is the molecular weight of the linked phosphate calculated 




Enzymatic degradation test of cross-connection matrix xanthan 
gum-amylose processing
Equivalent to 50 mg of amylose from each excipient, CL6-Ko-A-XG and 
CL12-Ko-A-XG are dispersed in ratios of 1:1 (100 mg); 1:2 (150 mg), 
and 2:1 (75 mg) in a 100 mL 0.2 M phosphate buffer of 6.7 mM with 
a pH of 7.4 at 37°C for 10 minutes with constant stirring at 50 rpm. 
The alpha-amylase from pig pancreases is 58.33 mg dissolved in 10 mL 
of NaCl phosphate buffer with a pH of 7.4; taken 1 mL then added to 
medium (17.5 UI/100 mL medium). The sampling takes 1 mL at 15, 30, 
60, 90, 120, 180, 240, 360, and 480 minutes after incubation. Samples 
are mixed with 3 mL of HCl and 5 mL of 0.1 N of iodine, and then the 
sufficient volume went up to 10 mL the uptake is immediately measured 





Formulation of sustained-release tablet diclofenac sodium
The mass of the tablets is 500 mg and is made through direct forging 
method. Diclofenac sodium tablet formula is described in Table 1.
Evaluation of sustained-release diclofenac sodium tablets
Physical appearance
Aspects considered in a tablet’s physical appearance include its size, 
shape, color, and surface.
Uniformity of weight
A total of 20 tablets are weighed and then the average weight of each 
tablet is calculated. If weighed one by one, only two tablets will have 
a weight that deviates from the average weight more than what is 
specified by column A, and none weigh more than the average as 
denoted by column B [4] (Table 2).
Uniformity of size
A total of 20 tablets are chosen at random and then measured in 
diameter and thickness using a sliding range. Unless otherwise stated, 
the diameter is no more than 3 times and no <1 tablet thick [4].
Tablet firmness
Tablet firmness is determined using the friability tester tool. 20 
tablets are cleaned of dust, weighed, and then fed into the friability 
tester. The friability tester tool runs at 25 rpm for 4 minutes (100 lap 
times). Tablets are cleaned of dust and then weighed again. The weight 
difference before and after the treatment is calculated, where the tablet 
weight loss cannot exceed 1% [5]. Tablet firmness can be calculated 
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Test index expands slow tablet formula slow
The expanding index is tested using a tablet formula F1-F6 that has 
been printed into tablets, weighing ± 500 mg each. Each tablet is 
inserted into a Petri dish containing 10 mL of phosphate buffer medium 
with a pH of 7.4. The expanding index is measured through the increase 
in tablet weight, up to the 8th hr. Tablets are weighed at 15, 30, 60, 90, 
120, 180, 240, 360 and 480 minutes.
Dissolution test of diclofenac sodium tablet with and without 
addition of alpha-amylase
Quantitation of diclofenac sodium content in tablets
Quantitation of the diclofenac sodium content in tablets is done through 
UV-visible spectrophotometry method. Tablet powder equivalent to 
50 mg diclofenac sodium is weighed, incorporated into a 100.0 mL 
measuring flask, and then dissolved with 0.1 N sodium hydroxide up to 
the limit. It is then filtered and 10 mL of the first filtrate is discarded. 
After that the filtrate is piped in 2 mL and then put into a 100 mL 
measuring flask, with 0.1N sodium hydroxide added to the limit. The 
absorption is measured at its maximum wavelength. Meanwhile, to 
interpret the results, a calibration curve of standard BPFI diclofenac 
sodium is prepared with concentrations of 4 ppm, 6 ppm, 8 ppm, 
10 ppm, 12 ppm, 14 ppm, and 16 ppm in 0.1 N sodium hydroxide. Tablets 
are said to qualify if they contain diclofenac sodium 90.0-110.0% of the 
value listed on the label.
Drug release (dissolution) test
The diclofenac sodium dissolution test of a sustained-release tablet of 
diclofenac sodium is carried out using a type-2 dissolution device that 
is a type of paddle and conducted in two mediums, that is, in a 900 mL 
medium of 0.2 M phosphate buffer pH 7.4 and 900 mL of 6.7 mM 
phosphate buffer medium at pH 7.4 containing alpha-amylase. The 
dissolution medium is maintained at 37±0.5°C with a 50 rpm stirring 
speed.
Samples are taken at minute 15, 30, 60, 90, 120, 180, 240, 360, and 480. 
Then, the amount of diclofenac sodium dissolved is measured using 
a UV-visible spectrophotometer at maximum wavelength (276 nm), 
using the phosphate buffer 0.2 M pH 7.4 solution as the blank control. If 
necessary, dilution of the filtrate has been taken [6].
The calculation of the cumulative amount of diclofenac sodium 
dissolved at a given time is:















Wt = The cumulative amount of diclofenac sodium is de-dissolved at time t
W0 = The amount of sodium diclofenac present in the matrix
C = Concentration of diclofenac sodium which is dissolved at time t
V1 = Dissolution test fluid volume
V2 = Volume of pipetted fluid.
Dissolution data are calculated using the drug release kinetics model. The 
test is also conducted to determine the dissolution mechanism that occurs.
RESULTS AND DISCUSSION
The synthesis of excipients of cross-connection xanthan gum-amylose 
processing is shown in Table 3. In addition, Table 4 shows the 
substitution degrees.
Enzymatic degradation test of excipients
Evaluation of sustained-release diclofenac sodium tablets, according 
to the mass evaluation of tablets, is shown in Table 5. Further, tablet 
weight uniformity, size uniformity, and tablet hardness are described in 
Tables 6-8, respectively.
Index expands
Dissolution test of diclofenac sodium tablet with and without addition 
of alpha-amylase, and the quantitation of diclofenac sodium content in 
tablets are shown in Table 9.
Release (dissolution) drug test
Fig. 1 shows that the drug release profile of F2 in the medium containing 
the enzyme is not affected by alpha-amylase. Formulas 1 and 3 have a 
slower drug release than those in a non-enzyme medium.
Table 1: Diclofenac sodium tablet formula
Materials F1 F2 F3 F4 F5 F6
Sodium diclofenac 75 75 75 75 75 75
CL6-Ko-A-XG (1:1) 300 - - - - -
CL6-Ko-A-XG (1:2) - 300 - - - -
CL6-Ko-A-XG (2:1) - - 300 - - -
CL12-Ko-A-XG (1:1) - - - 300 - -
CL12-Ko-A-XG (1:2) - - - - 300 -
CL12-Ko-A-XG (2:1) - - - - - 300
Avicel PH 102 125 125 125 125 125 125
Total (mg) 500 500 500 500 500 500
CL6-Ko-A-XG: Cross-linked excipient with 6% STMP amylose-xanthan 
gum process. CL12-Ko-A-XG: Cross-linked excipient with 12% STMP 
amylose-xanthan gum process
Table 2: Weight uniformity requirements
Average weight Average weight aberration 
in%
A B
25 mg or less 15 30
26-150 mg 10 20
150-300 mg 7.5 15
More than 300 mg 5 10
Source: Ministry of Health Republic of Indonesia, 1979
Table 3: The percentage yield of excipients synthesis of the 












Table 4: Data of % P and degree of substitution excipients 
CL6-Ko-A-XG and CL12-Ko-A-XG
Excipients % p DS
CL6-Ko-A-XG (1:1) 1.91±0.095 0.099±0.006
CL6-Ko-A-XG (1:2) 1.77±0.095 0.090±0.006
CL6-Ko-A-XG (2:1) 1.77±0.072 0.090±0.004
CL12-Ko-A-XG (1:1) 4.78±0.176 0.289±0.013
CL12-Ko-A-XG (1:2) 4.55±0.147 0.272±0.011
CL12-Ko-A-XG (2:1) 4.42±0.152 0.262±0.011
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According to Fig. 2, the drug release profiles of the F4, F5, and F6 matrix 
tablets are not affected by the presence of enzymes. This is due to the 
use of high concentration cross-linked agents, which cause the tablet to 
be more resistant to enzymatic degradation. Data of kinetic calculation 
of diclofenac sodium dissolution are shown in Table 10.
DISCUSSION
In preparing this excipient, xanthan gum-amylose is processed first. It 
is cross-linked using STMP at a temperature of 300°C. Based on Cury 
et al., a temperature of 300°C is the optimum temperature for the cross-
linking reaction [7]. The 3% w/v dispersion of Co-A-XG is then added, 
with 10 N NaOH solution used to maintain the pH during the reaction 
of 11-12. Then, the reaction is left for the next 12 hrs without stirring 
to ensure the reaction is complete. The reaction is declared complete if 
the pH has not decreased due to the presence of H+ released from the 
phosphate substitution.
The alkaline pH conditions at the time of cross-linking are required 
to open the STMP ring into sodium tripolyphosphate. In addition, 
the amylose and/or xanthan gum hydroxyl groups are ionized and 
may attack the phosphate in sodium tripolyphosphate under basic 
pH conditions. The reaction produces amylose and/or xanthan gum 
pyrophosphate. Amylose and/or xanthan gum pyrophosphate may be 
attacked by an amylose hydroxyl group and/or xanthan gum, further 
resulting in amylose or di-xanthan gum phosphates [8].
After the reaction is complete, the mixture is neutralized using a 7 N 
HCl solution until it reaches pH 6. Neutralization with the addition of 
HCl aims to replace the previously lost H+ amylose proton and does not 
react with STMP [7]. The neutralized solution mixture is washed using 
96% ethanol through the decantation principle to dissolve short-chain 
polysaccharides. The CL6-Ko-A-XG and CL12-Ko-A-XG excipients of 1:1, 
1:2, and 2:1 ratios are produced as fine, odorless, and slightly yellowish-
white granules.
Substitution degrees
In this study, the degree of excipient substitution is calculated against 
the number of hydroxy groups of amylose and possibly xanthan gum 
substituted by the phosphate group. Amylose has 3 hydroxy groups in 
each glucose unit at positions C-2, C-3, and C-6. The most reactive and 
easily substituted hydroxy group is that at position C-6 since it is the 
primary alcohol [9].
The determination of degrees of substitution is performed through 
colorimetric method [10]. Inorganic phosphates resulting from the 
decomposition of organic substances in excipients with annealing react 
Table 5: Mass evaluation data of F1-F6 tablets
Formula Flow rate (gram/second) Repose angle (0) Hausner ratio Compressibility index (%) Category
1 5.05±0.13 34.63±1.14 1.15±0.01 12.78±0.96 Good
2 5.59±0.11 33.96±1.14 1.15±0.01 12.78±0.96 Good
3 5.39±0.03 35.61±0.56 1.13±0.02 11.11±1.92 Good
4 5.97±0.12 29.74±0.00 1.17±0.01 16.89±1.31 Special
5 4.33±0.16 33.97±1.14 1.23±0.02 12.54±2.47 Good
6 4.94±0.32 31.98±0.20 1.16±0.01 13.89±0.96 Good
Table 6: The result of uniform weight evaluation of F1-F6 tablets







Table 7: Results of uniform size evaluation of sustained-release 
tablets F1-F6
Formula Diameter (cm) Thickness (cm) Diameter/
thickness (cm)
1 1.22±0.00 0.33±0.04 3.68±0.05
2 1.22±0.00 0.33±0.00 3.66±0.05
3 1.22±0.00 0.33±0.00 3.67±0.05
4 1.22±0.00 0.33±0.00 3.67±0.05
5 1.22±0.00 0.33±0.00 3.67±0.05
6 1.22±0.00 0.33±0.01 3.66±0.05
Table 8: Results of evaluation of hardness and firmness of 
sustained-release tablets F1-F6















Table 10: Data of kinetic calculation of diclofenac sodium 
dissolution from F1-F6 matrix
Formula Parameters Zero order Korsmeyer–Peppas
1 r 0.987±0.002 0.990±0.004
k 0.182±0.002 0.873±0.083
n 0.741±0.012
2 r 0.988±0.007 0.991±0.007
k 0.103±0.006 0.765±0.231
n 0.639±0.016
3 r 0.991±0.001 0.986±0.004
k 0.165±0.004 0.746±0.065
n 0.712±0.014
4 r 0.998±0 0.979±0.004
k 0.097±0.003 0.688±0.006
n 0.643±0.001
5 r 0.995±0.001 0.984±0.001
k 0.095±0.006 0.705±0.016
n 0.645±0.012
6 r 0.979±0.003 0.971±0.001
k 0.435±0.016 0.677±0.016
n 0.840±0.009
K: Drug dissolution constant for each equation, N: Peppas diffusion exponent
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with ammonium molybdate to form the phosphomolybdate complex. 
The phosphomolybdate complex is reduced by ascorbic acid to produce 
a blue complex.
The degree of excipient substitution does not affect the physical 
characteristics of excipients, but it affects the functional characteristics 
of the excipients, namely, the expanding index, gel strength, and 
viscosity which will affect the ability to release the drug from the 
excipient matrix.
Enzymatic excipient degradation test
The degradation tests on CL6-Ko-A-XG and CL12-Ko-A-XG are each 
performed for 60 minutes because the absorption after that time frame 
did not fall within the 0.2-0.8 range, so the test was not sensitive and 
accurate. In amylose, the degradation test is also performed, but during 
minute 15 of the test, no amylose was discontinued because it had 
degraded; no calculations could be performed.
Fig. 3 shows the enzymatic degradation of 1:1, 1:2, and 2:1 CL6-Ko-
A-XG as well as 1:1, 1:2, and 2:1 CL12-Co-A-XG excipients. It showed 
that CL12-K-A-XG degraded less than CL6-Ko-A-XG. This is because the 
amount of xanthan gum in the excipient is greater, where xanthan is 
resistant to enzymatic erosion [11]. In addition, not only does amylose 
undergo cross-linking but xanthan gum also does. The amount of 
xanthan gum needed to mask the amylose, thus inhibiting enzymatic 
degradation, is double.
The CL12-Ko-A-XG 1:2 excipient was degraded less than CL6-Ko-A-XG 
1:2. In CL12-Ko-A-XG 1:2, the amylose remained at 66.80%, whereas 
CL6-Ko-A-XG 1:2 was 37.48% within 1 hr. Larger STMP concentrations 
lead to more cross-linking in amylose and possibly xanthan gum. Cross-
linking decreases the enzyme’s ability to enter into the excipient, so the 
higher the concentration of the shelling agent, the more resistant it is to 
enzymatic degradation. The bond strength of amylose provides a stable 
and acid-resistant structure, enzymatic hydrolysis, and heat and shear 
stress. Overall, the CL12-Ko-A-XG excipient degraded less than CL6-Ko-
A-XG with the remaining amylose counts of 37.48-44.9% and 66.80-
75.29% for 1 hr of testing. 20% of the CL6-Ko-A-XG and CL12-Ko-A-XG 
excipients had degraded at the 10 and 30 minutes marks, which in the 
experiments showed an 80% amylose residue. Thus, the concentration 
of STMP and the amylose-xanthan gum concentration ratio used affects 
the excipient enzyme degradation.
Making sustained-release diclofenac sodium tablets
The addition of Avicel PH 102 is used as a binder. This is because at 
the time of the tablet printing process using a tablet machine, tablets 
that were not produced to meet the requirements of 10-20 kP hardness, 
so the tablet becomes fragile and cracked. In this sustained-release 
formulation, instead of being used solely as a binder, Avicel PH 102 also 
serves as a lubricant [11] that can prevent the tablets from sticking with 
punch and dye when printed using a tablet press. Powder evaluation 
occurs before the printing of tablets.
Mass evaluation of tablets
Mass evaluation is performed before tablet preparation. Evaluations 
performed include flow rate test, compressibility index test, repose 
angle test, and Hausner ratio test to assess the flow properties of the 
powder. Good flow properties will ensure weight uniformity. The better 
flow properties will ensure a full fill that is evenly distributed so that 
the weights are all uniform [12].
In addition to the flow rate, flow properties are also influenced by the 
angle of repose. The repose angle is the maximum angle that exists 
Fig. 1: Drug release profile tablets F1, F2, and F3. In phosphate 
buffer medium pH 7.4 without enzyme and with enzyme, each 
point illustrates the mean ± SD (n=3)
Fig. 2: Drug release profile tablets F4, F5, and F6. In phosphate 
buffer medium pH 7.4 without enzyme and with enzyme, each 
point illustrates the mean ± SD (n=3)
Fig. 3: Enzymatic degradation of excipients for 60 minutes. Each 
dots shows the average value (mean) ± SD (n=3)
Table 11. Data of kinetic calculation of diclofenac sodium 
release from F1-F6 matrix
Formula Parameters Zero order  Korsmeyer-Peppas
1 r 0.987±0.002 0.990±0.004
k 0.182±0.002 0.873±0.083
n 0.741±0.012
2 r 0.988±0.007 0.991±0.007
k 0.103±0.006 0.765±0.231
n 0.639±0.016
3 r 0.991±0.001 0.986±0.004
k 0.165±0.004 0.746±0.065
n 0.712±0.014
4 r 0.998±0 0.979±0.004
k 0.097±0.003 0.688±0.006
n 0.643±0.001
5 r 0.995±0.001 0.984±0.001
k 0.095±0.006 0.705±0.016
n 0.645±0.012
6 r 0.979±0.003 0.971±0.001
k 0.435±0.016 0.677±0.016
n 0.840±0.009
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between the surface of a powder stack and the horizontal plane, 
indicating the frictional force between the powder particles. A non-
cohesive powder can flow well, spread, and form a low heap [12]. The 
smaller (sloping) the angle of repose, the better the flowing properties 
of a powder and vice versa [13].
Evaluation of sustained-released diclofenac sodium tablet
Physical appearance
Tablets are formulated as round, flat, brownish-white, and odorless. 
The physical appearance of tablets can be seen in Fig. 4.
Tablet weight uniformity
Based on Table 7, F1-F6 tablet evaluation results are eligible, thus 
there is no deviation from Column A (5%) and Column B (10%) from 
the average weight of each tablet formula, according to Pharmacopoeia 
Indonesia edition III.
Size uniformity
Based on Table 8, No formula meets the requirements of Pharmacopoeia 
Indonesia III edition because the tablet diameter is more than three 
times the thickness of the tablet. However, these requirements have 
been excluded on the IV Pharmacopoeia.
Tablet hardness
Hardness is useful as a physical control during the manufacturing 
process. Tablet rigidity is useful for knowing how resistant tablets 
are to shocks that occur during manufacturing, packaging, and 
distribution [14]. The hardness value of the tablet will generally be 
correlated with the randomness value of the tablet (Table 9). The 
harder a tablet is, the smaller the value of its rigidity, and vice versa. The 
hardness of the tablet is influenced by the amount of pressure exerted 
during production as well as the mass particle shape of the tablet. 
According to Table 9, these six formulas qualify where the weight loss 
in the assay test is no more than 1%, according to USP 30.
Index expands tablet formula
An index that expands a tablet formula in a medium may affect the 
release of the drug from the excipient to a particular medium. Testing 
of the expanding index is carried out on the formula of diclofenac 
sodium F1-F6 tablets on a phosphate buffer base with a medium 
pH of 7.4 for 480 minutes. This condition will show the correlation 
between index-expanded formulas of F1-F6 tablets with the tablets’ 
drug release.
Fig. 5 shows the different indexes inflate each formula’s tablet. This 
is related to the difference in tablet speed for hydrated and hydrogel 
strength of tablet formulations in the phosphate buffer with a medium 
pH of 7.4. In the tablet formulation using CL6-Ko-A-XG excipients, CL6-
Ko-A-XG 1:2 (F2) has the smallest expanding index compared to CL6-
Ko-A-XG 1:1 (F1) and CL6-Ko -A-XG 2:1 (F3). Tablet F2 has an expanded 
index value of 265.71%, whereas F1 and F3 have values of 407.20% 
and 451.98%, respectively. The formulation of tablets with CL12-Ko-
A-XG 1:2 (F5) excipients show the smallest expansion index value of 
238.88%, whereas CL12-Ko-A-XG 1:1 (F4) and CL12-Ko-A-XG 2:1 (F6) 
have index values of 281.41% and 803.95%, respectively. This is due 
to the greater amount of xanthan gum, where xanthan gum has a good 
expanding index in the medium [8].
The index inflated F4 tablet is smaller than F1 and F5 expands less than 
F2. The concentration of dysfunctional agents affects the index and 
expands the tablets. In the CL-Ko-A-XG excipient, the excipients are not 
only amylose but also cross-linked xanthan gum. In F4 and F5, the STMP 
concentrations used are greater than F1 and F2, so more hydrophilic 
groups are substituted by phosphates. Xanthan gum has gel strength 
and a good expanding index [11]. If the xanthan gum is dysfunctional, 
the xanthan gum chain bond will become stronger. Cross-linking 
xanthan gum will make the macromolecule matrix stiff so that the index 
expands the declining tablets [8].
Formula 6 has an expanded index larger than F3 and other formulas. 
This relates to the amount of amylose and STMP in the excipient. 
A greater the amount of amylose than the amount of xanthan gum 
(2:1) causes the excipient to be more easily hydrated, resulting in a 
larger expanded index. In addition, the STMP concentration used is 
greater than F3. Administrated amylose with low-to-moderate STMP 
concentrations will result in a closer chain linkage by strengthening 
hydrogen bonds with strong covalent bonds. At high concentrations of 
STMP, many glycemic bridges are found in chains, hydrogen bonds are 
blocked, and chain links are more loosely coupled with intermediate 
chain regulation, so the larger the index expands [15].
Determination of tablet content
This evaluation is performed to determine the dosage of the active 
substance in a precise pharmaceutical preparation. The pharmaceutical 
preparation will not cause the expected therapeutic effect if used not 
according to the range of active substance, or if the active ingredient is 
less than the dosage. If the content of an active substance is excessive, it 
can cause toxic effects.
The assay results in Table 10 show that the active ingredient is in the 
range 90.0-110.0%, thus meeting the requirements of USP 30.
Drug release (dissolution) test
In the preparation of sustained-release tablets, the dissolution 
test is crucial for understanding the drug’s release from the tablet 
matrix. In this case, diclofenac sodium is used as a drug model. 
The sustained-release tablets are expected to retain the diclofenac 
sodium acid release in the phosphate buffering medium at a pH 
Fig. 4: Physical appearance of F1 tablets; F2; F3; F4; F5; and F6
Fig. 5: Index inflate tablet F1-F6. Each point illustrates the mean 
± SD (n=3)
Fig. 6: Drug release profile of the formulation tablet with CL6-Ko-
A-XG excipient (F1-F3) and with CL6-Ko-A-XG excipient (F4-F6) 
in a phosphate buffer buffer pH 7.4 without enzyme. Each point 
represents the mean ± SD (n=3)
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of 7.4. The medium is used in accordance with the United States 
Phamacopoeia 32nd ed. [6]. The diclofenac sodium has pKa = 4, so 
the diclofenac sodium is soluble in alkaline pH and insoluble in 
acid solution. When the drug is soluble, the preparation will release 
the drug into the medium. The amount of potassium dihydrogen 
phosphate used in accordance with the literature will simulate 
conditions in the small intestine [16].
The drug release profile of diclofenac sodium from the matrix can be 
seen in Fig. 6. Formulas 1 to 3 are tablet formulas using the CL6-Ko-
A-XG matrix with ratios of 1:1, 1:2, and 2:1. The diclofenac sodium 
release profile shows that F2 can withstand drug release for 8 hrs 
with a cumulative amount of 49.76%, whereas F1 and F3 indicate drug 
releases greater than 75-77.99% and 96.53%, respectively. This result 
is consistent with the inflate index of tablets showing F2 having the 
smallest expanding index, whereas F3 has the largest of the tablets with 
the CL6-Ko-A-XG excipient.
In tablets with CL12-Ko-A-XG excipients, F5 showed the smallest drug 
release compared to F4 and F6, at 45.90%. Formula 4 releases the drug 
by 47.66% after 8 hrs while F6 releases the drug as much as 92.18% after 
8 hrs. This is consistent with the inflate index of tablets (Fig. 5), where 
tablets with excipient formulations having larger xanthan gum ratios 
have smaller expanding indices. Xanthan gum has a good expanding 
index in the medium so it can withstand a longer drug release [8].
A comparison of dissolution profiles between tablets with CL6-Ko-A-XG 
and CL12-Ko-A-XG excipients in Fig. 6 shows that Formula 4 releases the 
drug more slowly than F1. Similarly, F5 releases the drug more slowly 
than F2. As the index profile expands (Fig. 5), the index inflate F4 tablet 
is smaller than F1 and F5 is smaller than F2. This may be because not 
only amylose is found in the crosslinked xanthan gum-amylose xanthan 
excipients, but also xanthan gum. Thus, the higher the concentration of 
STMP in the matrix, the more the hydrophilic amylose and xanthan gum 
groups are substituted by the phosphate, the smaller the index expands 
the tablet, and the less the amount of the drug dissolved. Formula 6 
shows a drug release profile faster than F3 and other forms. This is 
consistent with the rapid expansion index of tablets (Fig. 5).
Formula 6 releases the active substance quickly. This corresponds to 
the F6 index inflate rapidly expanding up to 240 minutes (Fig. 5). In 
addition, the F6 contains a 2:1 amylose-xanthan gum ratio with a 12% 
STMP concentration. The number of cross-linked amylose with higher 
STMP concentrations is greater than xanthan gum. Amylose with a 
dysregulatory concentration of more than 10 results in cross-linked 
amylose showing a decrease in drug release time. The three-dimensional 
structure of amylose hydrogel with high STMP concentrations resulted 
in a more split structure when compared to amylose with low-to-
moderate STMP concentrations [15]. The structure causes water to 
penetrate more easily so the tablet expands faster.
Furthermore, the drug release test is carried out in an enzyme-
containing medium. The enzyme used is alpha-amylase because 
the amylose present in the excipient CL-Ko-A-XG is a substrate of 
alpha-amylase. The medium used is a phosphate buffer at a pH of 7.4 
containing 6.7 mM NaCl. The amount of NaCl added is in accordance 
with the Sigma-Aldrich protocol, and is intended to keep the enzyme 
activity in the medium.
Fig. 1 shows that the drug release profile of F2 in the medium containing 
the enzyme is not affected by alpha-amylase. Formulas 1 and 3 have a 
slower drug release than those in a non-enzyme medium. This is due to 
the presence of electrolytes in the dissolution medium. Sodium chloride 
added to the dissolution medium will form Na+ and Cl- ions, which will 
decrease the expanding ability of cross-linked amylose. The presence 
of electrostatic interactions between amylose and sodium chloride 
and the competition between amylose and sodium chloride in binding 
water molecules causes a decrease in the expanding ability of cross-
linked amylose [17].
According to Fig. 2, the drug release profiles of the F4, F5, and F6 
matrix tablets are not affected by the presence of enzymes. This is due 
to the use of high concentration cross-linked agents, which cause the 
tablet to be more resistant to enzymatic degradation. The higher the 
concentration of dysfunctional agents, the lower the enzyme’s ability to 
enter the excipient. The bond strength of the amylose provides a stable 
and acid-resistant structure, enzymatic hydrolysis, and heat and shear 
stress. In the enzymatic degradation test of excipients in powder form, 
the presence of alpha-amylase was to ensure ease of degradation, but 
after being formulated and forged into tablets, the drug release is not 
affected by its presence.
To relate the frequency of drug administration in daily use to the amount 
of soluble drugs, the Banakar rules are applied. If the percentage of the 
solution is about 20-45%, then a sustained-release preparation can 
be used for 32 hrs. If the percentage of drug that dissolves is around 
45-75%, it can be used for 16 hrs. If the percentage of the drug that 
dissolves is over 75%, then the sustained-release preparation can only 
be used for 8 hrs. According to Fig. 6, the percentage data relating to 
the amount of drug released in a phosphate buffer medium with a pH 
of 7.4 without enzymes for 8 hrs, Formulas 2, 4, and 5 fell between 45% 
and 75%. According to Banakar rules, they can be used as sustained-
release tablets for 16 hrs. In a matrix of tablets with 1:1 (F4) and 1:2 
(F5), CL6-Ko-A-XG 1:2 (F2) and CL12-Ko-A-XG matrices having slow-
expanding indices. Thus, the amount of diclofenac sodium released by 
them is less. In F1, F3, and F6, the percentage of drug quantity released 
is over 75%, so according to the Banakar rule, they can be used as a 
sustained-release tablet formula for 8 hrs. However, there is a slowing 
of the drug release in F1 and F3 when in phosphate buffer medium with 
a pH of 7.4 and alpha-amylase. According to Fig. 1, the percentage of 
the released drug is in the range of 45-75%, which according to the 
Banakar rule, means it can be used as a 16-hrs sustained-release tablet. 
This is due to the influence of electrolytes in the medium, which leads 
to a decrease in its ability to inflate amylose cross-link excipients [17]. 
Figs. 1 and 2 show no change in the drug release profile of F1-F6 in a 
phosphate buffer medium with a pH of 7.4 and alpha-amylase.
Furthermore, the drug release profile obtained from the six formulas 
is matched by analyzing them against some drug release kinetics, such 
as kinetics of zero-order release, first order, Higuchi, and Korsmeyer–
Peppas. In each kinetic equation matched with a prepared drug release, 
the value of the drug release constants (k) and correlation coefficient (r) 
will be obtained. If a preparation follows zero-order kinetics, then the 
rate of drug release is constant over time without being affected by the 
concentration of the drug [18].
Based on Table 11, it is shown that drug releases F1-F6 follow the 
kinetics of drug release of zero order and Korsmeyer–Peppas. This 
can be seen by the value of r at the zero order being near zero, and 
the value of n at Korsmeyer–Peppas being between 0.60 and 0.87. If a 
preparation follows zero-order kinetics, then the rate of drug release 
is constant over time without being affected by the concentration of 
the drug. The Korsmeyer–Peppas equation describes the drug release 
mechanism of a preparation based on a Fickian diffusion mechanism, 
a non-Fickian transport, or a super case-II transport mechanism based 
on the Peppas diffusion exponent value (n) [18].
CONCLUSION
The excipients CL6-Ko-A-XG and CL12-Ko-A-XG degraded by 20% 
(indicated by the remaining 80% amylose) at 10 minutes and 30 minutes 
degradation test with alpha-amylase, respectively. The dissolution profiles 
of tablet formulations with CL6-Ko-A-XG 1:2, CL12-Ko-A-XG 1:1, and 1:2 
excipients were not affected by enzymatic degradation and can be used 
for 16 hrs, whereas the tablet formulation with excipients CL6-Ko-A-XG 
2:1 and CL12-Ko-A-XG 2:1 underwent a change in dissolution profile to be 
slower and can be used for a sustained-release tablet of 8 hrs.
The xanthan gum-amylose cross-linking process can be an alternative 
to producing more functional excipients as sustained-release tablets 
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without the need for additional excipients in the formula. In addition, 
further research on the cross-linking of xanthan gum in CL-Ko-A-XG 
excipients is required.
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